Report an accessibility problem

RFP for Pre-clinical and Translational Research in Multiple Myeloma

Sponsors:
Pfizer
Amount:
$150,000
External Deadline:
09/28/21
Opportunity Information:

Pfizer has issued an RFP for its Pre-clinical and Translational Research in Multiple Myeloma grant program.

Grants of up to $150,000 will be awarded in support of pre-clinical and translational research in multiple myeloma. Only pre-clinical projects with a focus on these areas of interest will be considered: correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy; understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS) in the context of bispecific treatment; mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion); correlation between soluble BCMA and BCMA expression on myeloma cells (including assessment of gamma secretase activity); impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations); mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity; exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) with a focus on drugs that are not currently SOC in myeloma; immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity; and comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab.

Studies can be in-vitro or in-vivo or use existing patient samples (e.g., blood, bone marrow aspirates). A limited amount of the Pfizer asset elranatamab (PF-06863135) is available and can be requested through this RFP for non-clinical studies.

The applicant (principal investigator) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in pharmacy. Applicant must be affiliated with a host institution, and only organizations are eligible to receive grants, not individuals or medical practice groups.

For complete program guidelines and application instructions, see the Pfizer website.

ASU Information:

Submissions to this sponsor/donor are managed by the Office of Corporate and Foundation Relations. Please contact your unit-assigned ASUF Director of Development or Research Advancement Specialist at your earliest convenience to ensure ASU's strategic coordination and management of funding applications.

Posted Date: